BEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and ...

Exousia Pro, Inc., a clinical-stage biotech company that specializes in the use of exomes to treat cancer and other illnesses ...

An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...

Exousia Pro's subsidiary, Exousia AI, along with Dr. Marvin S. Hausman, filed for Orphan Drug Designation last year for its exosome-based GBM treatment. The ODD approved by the FDA opens a world of ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 ...

BRISBANE, Australia, Oct. 7, 2025 /PRNewswire/ -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully ...

Half of patients with GBM present with headaches at diagnosis, which is attributed to increases in intracranial pressure (Table 2). 11 Papilledema, now rarely seen because imaging is typically ...

FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a ...

Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma No significant financial ...

April 26, 2006 (San Francisco) --- Glioblastoma multiforme patients treated with a peptide vaccine after gross total resection and standard therapy have a median survival beyond 18 months, researchers ...